Serious Gram-negative (GN) pathogens are clinically-important pathogens in both the hospital and outpatient settings. GN pathogens are often acquired in healthcare facilities, and therefore have a high incidence of drug resistance to even the most powerful of antibiotics (e.g. third-generation cephalosporins, fluoroquinolones, and carbapenems). The increase in emergence of drug resistance, including resistance to multiple classes of antibiotics and the dearth of newly approved agents in the last ten years has resulted in a high need for new therapies for multi-drug-resistant (MDR) GN pathogens.
This report provides insight into the management of patients with GN infections in the hospital setting and analyzes the hospital antibiotic prescribing practices for the treatment of key infections due to emerging and clinically-important Gram-negative pathogens in Europe. The study provides longitudinal information on market dynamics, including insight into practice patterns, attitudes and perceptions, unmet needs, and projected use of antibiotics in the hospital setting. These studies also explore the perceived advantages and disadvantages of currently available therapies and therapies in development.
Questions Answered in This Report:
- - How are physicians treating serious infections due to emerging and clinically-important GN pathogens? Which pathogens are of concern to physicians, and which pose new treatment challenges and drug development opportunities? How is the threat of drug resistance im-pacting prescribing behavior?
- - How do physicians make treatment choices for GN infections, includ-ing empiric treatment for suspected GN infections?
- - How are European physicians treating severe skin infections, blood stream infections, nosocomial pneumonia, intra-abdominal infections, and complicated urinary tract infections?
- - What are physicians’ therapy preferences and what factors and drug attributes influence current and future prescribing patterns? How re-ceptive are physicians to novel and emerging therapies?
Sample Frame & Methodology:
- 125 infectious diseases and 125 critical care specialists complete a 45-minute online quantitative survey with several open-ended questions for qualitative feedback.
To qualify, respondents must meet the following criteria:
- Be board-certified in infectious diseases or critical care/intensive care
- Treated a minimum of 25 patients with Gram-negative infections within the last month
- Have been in practice a minimum of 2 years and a maximum of 30 years
- At least 50 percent of time practicing in the hospital setting
Key Drugs Covered:
- Meronem/Merrem (meropenem), Pri-maxin/Tienam (imipenem/cilastatin), Doribax (doripenem), Invanz (ertapenem), Tygacil (tigecycline), Tazocin/Tazocel/Tazobac (piperacillin/tazobactam), Tavanic(levofloxacin), Avalox/Izilox/Actira (moxifloxacin), key generic competi-tion, and emerging therapies, includ-ing Zeftera/Zevtera (ceftobiprole), CXA-201, and CAZ-AVI
Key Companies Mentioned:
- AstraZeneca, Basilea, Cubist, Johnson and Johnson / Janssen, Merck, and Pfizer
- Final report in Powerpoint format
- Complete set of frequency tables, summary statistics, and cross tabulations can be provided upon request
- Proprietary question slide deck: Clients purchasing report prior to fielding will have the opportunity to include up to three proprietary questions
- DecisionBase®: Gram-Negative Infections
- DecisionBase®: MRSA and Complicated Skin and Skin Structure Infections
- Pharmacor®: Hospital-Treated Gram-Negative Infections
- Pharmacor®: Hospital-Treated Infections
- Physician and Payer Forum® (U.S.): Gram-Negative Infections
- Physician and Payer Forum® (U.S.): MRSA Infections
- Physician and Payer Forum® (China): Hospital-Treated Infections
- TreatmentTrends® (U.S): Hospital Discharge and Outpatient Trends
- TreatmentTrends® (U.S.): MRSA Infections